Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M. Dinmohamed AG, et al. Among authors: sonneveld p. Leukemia. 2015 Dec;29(12):2449-51. doi: 10.1038/leu.2015.220. Epub 2015 Sep 15. Leukemia. 2015. PMID: 26369829 No abstract available.
Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.
Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M. Dinmohamed AG, et al. Among authors: sonneveld p. Leukemia. 2016 Jan;30(1):24-31. doi: 10.1038/leu.2015.188. Epub 2015 Jul 17. Leukemia. 2016. PMID: 26183645
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Daenen S, Löwenberg B, Sonneveld P, van Putten WL, Verhoef G, Verdonck LF, van Veldhoven M, Huijgens PC. Daenen S, et al. Among authors: sonneveld p. Leukemia. 1994 Jan;8(1):6-10. Leukemia. 1994. PMID: 8289499 Clinical Trial.
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.
Ossenkoppele GJ, van der Holt B, Verhoef GE, Daenen SM, Verdonck LF, Sonneveld P, Wijermans PW, van der Lelie J, van Putten WL, Löwenberg B. Ossenkoppele GJ, et al. Among authors: sonneveld p. Leukemia. 1999 Aug;13(8):1207-13. doi: 10.1038/sj.leu.2401478. Leukemia. 1999. PMID: 10450748 Clinical Trial.
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
Löwenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, Ferrant A, Sonneveld P, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, Breems D, de Muijnck H, Schaafsma R, Verhoef G, Döhner H, Gratwohl A, Pabst T, Ossenkoppele GJ, Maertens J; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German Austrian AML Study Group (AMLSG); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK). Löwenberg B, et al. Among authors: sonneveld p. Blood. 2010 Apr 1;115(13):2586-91. doi: 10.1182/blood-2009-10-246470. Epub 2010 Jan 26. Blood. 2010. PMID: 20103782 Free article. Clinical Trial.
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Dekker AW, van't Veer MB, Sizoo W, Haak HL, van der Lelie J, Ossenkoppele G, Huijgens PC, Schouten HC, Sonneveld P, Willemze R, Verdonck LF, van Putten WL, Löwenberg B. Dekker AW, et al. Among authors: sonneveld p. J Clin Oncol. 1997 Feb;15(2):476-82. doi: 10.1200/JCO.1997.15.2.476. J Clin Oncol. 1997. PMID: 9053468 Clinical Trial.
630 results